News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Ultragenyx Reports Promising Phase III Clinical Trial Results for Urea Cycle Disorder Treatment
Ultragenyx’s gene therapy DTX301, based on technology invented by Jim Wilson, MD, PhD, Emeritus Professor at Penn Medicine, helped control ammonia levels in patients with a urea cycle disorder.
Previous President’s Innovation Prize Winners Recognized in Technical.ly’s RealLIST
Both companies are Penn I-Corps graduates.
Serpent Robotics Wins 2026 President’s Innovation Prize
Serpent Robotics, founded by Wharton undergraduate Margaret Zhu, is developing an electric, rope‑climbing robotic system.
Avisi Technologies Raises $11M to Advance Glaucoma Treatment
The funding will support Avisi’s pivotal clinical trial for VisiPlate, a novel glaucoma treatment. device
Verismo Therapeutics Receives $28 million to Accelerate KIR-CAR Clinical Development
The funding from HLB Innovation, Verismo’s parent company, will advance clinical development of its killer cell immunoglobulin-like receptor (KIR)-chimeric antigen receptor (CAR) platform\.
Biogen to Acquire Apellis for $5.6B
Apellis’ C3 complement therapies, Syfovre® and Empaveli® will expand Biogen's presence in immunology.
Penn and CHOP Scientists Win 2026 Breakthrough Prize for Developing Gene Therapy for Inherited Blindness
These faculty developed the first FDA-approved gene therapy for an inherited condition.
Meet the 2026/2027 PCI Invention Analysts Cohort
PCI welcomes the 2026 PCI Fellows consisting of 12 outstanding trainees across Penn’s schools: Penn Engineering (6), Penn Medicine (5), and Penn Arts & Sciences (1).
Investment Funds available for Penn Startups
Penn has three investment funds available for early stage startups affiliated with the University.
Executive Director of Bayh-Dole Coalition Explains the Current State of Bayh Dole
Joe Allen, Executive Director of the Bayh-Dole Coalition, shared insights about recent challenges to the Bayh-Dole Act,